Alger

Impulse Dynamics N.V. is a medical device company focused on developing electrical therapies for chronic heart failure, operating primarily in the United States and Europe. The company's key innovation is its cardiac contractility modulation (CCM) therapy, which utilizes non-excitatory electrical impulses delivered to the heart muscles. This therapy aims to enhance cardiac strength and improve blood flow, offering a minimally invasive treatment option for patients with limited alternatives. Impulse Dynamics conducts clinical trials to assess the safety and efficacy of its therapies and collaborates with universities and hospitals for research initiatives. Founded in 1996 and headquartered in Willemstad, Curacao, the company also maintains offices in New York and Hong Kong, alongside product development centers in New Jersey and Israel.

REDWOOD INVESTMENTS, an independent investment management boutique, specializes in managing Large and Small Capitalization Equity portfolios for institutional, foundation, endowment and private clients. Redwood also offers Sustainable Investing strategies that incorporate environmental, social and corporate governance (ESG) factors with traditional investment analysis. Portfolios are managed by an experienced investment team utilizing a sophisticated investment process. The portfolio management team employs a disciplined, fundamentally driven stock selection process which integrates in-depth bottom-up equity research informed by proprietary quantitative tools and an advanced portfolio optimization construction system – all aimed at delivering superior and consistent investment performance. In addition, Redwood’s entrepreneurial employee-owners aspire to deliver highly attentive client service.

Forte Biosciences is a biotechnology company specializing in dermatology and biopharmaceuticals. The company is developing innovative treatments for inflammatory skin diseases, with its lead product, FB-401, being a topically applied live biotherapeutic created in partnership with the National Institutes of Health and the National Institute of Allergy and Infectious Diseases. Additionally, Forte is advancing through preclinical trials for another product candidate, FB-102, which is a proprietary therapeutic molecule that may have applications in treating various autoimmune conditions, including graft-versus-host disease, vitiligo, and alopecia areata.

Impulse Dynamics N.V. is a medical device company focused on developing electrical therapies for chronic heart failure, operating primarily in the United States and Europe. The company's key innovation is its cardiac contractility modulation (CCM) therapy, which utilizes non-excitatory electrical impulses delivered to the heart muscles. This therapy aims to enhance cardiac strength and improve blood flow, offering a minimally invasive treatment option for patients with limited alternatives. Impulse Dynamics conducts clinical trials to assess the safety and efficacy of its therapies and collaborates with universities and hospitals for research initiatives. Founded in 1996 and headquartered in Willemstad, Curacao, the company also maintains offices in New York and Hong Kong, alongside product development centers in New Jersey and Israel.

Weatherbie Capital was founded in 1995 by Matthew Weatherbie and, similar to Alger, takes a fundamental, bottom-up research approach to investing in growth equities. Weatherbie Capital aims to identify and invest in attractive U.S. small- and mid-cap companies poised for growth. The firm’s flagship strategy, the Weatherbie Specialized Growth strategy, has, for its 20-plus years in existence, demonstrated a record of strong relative performance. Mr. Weatherbie will remain CEO and, again become Co-CIO, of Weatherbie Capital, which at closing, will become a wholly owned subsidiary of Alger.

Prosetta Biosciences, Inc. is a biotechnology company based in San Francisco, California, founded in 2002. It specializes in developing novel small-molecule antiviral therapeutics using an innovative drug discovery platform that employs cell-free protein synthesizing systems. This approach allows for the identification of active compounds that may be overlooked by traditional pharmaceutical screening methods. Prosetta's research addresses a broad range of human diseases, including oncology, neurodegenerative disorders, and infectious diseases, and the company collaborates with both commercial partners and non-profit organizations to advance its compounds. Through its efforts, Prosetta Biosciences aims to enable healthcare professionals to discover and utilize small molecules that effectively modulate the assembly of multi-protein complexes within cells.

Tolero Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing innovative therapeutics for cancer and other serious diseases in the United States. Founded in 2011 and based in Salt Lake City, Utah, Tolero's product pipeline includes several promising candidates. TP-0413 targets a signaling pathway involved in serum iron regulation for patients with chronic inflammatory diseases, while TP-0903 is a dual-targeted agent that inhibits pathways critical for pancreatic cancer cell growth and tumor maintenance. Additional compounds under development include TP-0829, which addresses B-cell lymphomas and leukemia, and TP-0227, aimed at endometrial carcinomas. The company also explores TP-1149 to combat drug resistance in myeloma cells. Tolero Pharmaceuticals operates as a subsidiary of Dainippon Sumitomo Pharma America Holdings, Inc. and has established a partnership with MannKind Corporation to enhance its therapeutic development efforts.

Tolero Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing innovative therapeutics for cancer and other serious diseases in the United States. Founded in 2011 and based in Salt Lake City, Utah, Tolero's product pipeline includes several promising candidates. TP-0413 targets a signaling pathway involved in serum iron regulation for patients with chronic inflammatory diseases, while TP-0903 is a dual-targeted agent that inhibits pathways critical for pancreatic cancer cell growth and tumor maintenance. Additional compounds under development include TP-0829, which addresses B-cell lymphomas and leukemia, and TP-0227, aimed at endometrial carcinomas. The company also explores TP-1149 to combat drug resistance in myeloma cells. Tolero Pharmaceuticals operates as a subsidiary of Dainippon Sumitomo Pharma America Holdings, Inc. and has established a partnership with MannKind Corporation to enhance its therapeutic development efforts.

ChoiceStream is a digital advertising service that specializes in programmatic advertising, focusing on cross-device branding and direct response campaigns for brand and agency clients. The company manages all phases of advertising campaigns, from pre-launch planning to completion, ensuring efficiency and effectiveness in reaching target audiences. By utilizing proprietary, poll-based data tailored to individual campaigns, ChoiceStream creates custom, targetable audiences and optimizes campaign results in real time. The company employs advanced machine-learning algorithms alongside a dedicated team of industry experts, which contributes to an impressive client retention rate of 83%, significantly higher than the industry average. This blend of innovative technology and personalized service enables clients to achieve their advertising goals effectively.